Post by AstraZeneca

Obesity rarely exists in isolation. New findings from the AstraZeneca-sponsored CALOR real-world evidence programme put numbers to what clinicians increasingly recognise: around 87% of people with obesity or overweight in the US already have at least one cardiorenal complication. With type 2 diabetes, that rises to around 99%. Many aren’t even aware until serious damage is done. These data make the case for earlier recognition and intervention —for science designed to change disease trajectories, not just body weight. As understanding of obesity continues to grow, there is an opportunity to move beyond weight alone and towards more comprehensive approaches to cardiometabolic health. Read more about the CALOR study here: https://lnkd.in/eugeb2-c #WhatScienceCanDo